PT  - JOURNAL ARTICLE
AU  - Áñez, Germán
AU  - Dunkle, Lisa M.
AU  - Gay, Cynthia L.
AU  - Kotloff, Karen L.
AU  - Adelglass, Jeffrey M.
AU  - Essink, Brandon
AU  - Campbell, James D.
AU  - Cloney-Clark, Shane
AU  - Zhu, Mingzhu
AU  - Plested, Joyce S.
AU  - Roychoudhury, Pavitra
AU  - Greninger, Alexander L.
AU  - Patel, Nita
AU  - McGarry, Alice
AU  - Woo, Wayne
AU  - Cho, Iksung
AU  - Glenn, Gregory M.
AU  - Dubovsky, Filip
AU  - ,
TI  - Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial
AID  - 10.1101/2022.09.20.22279903
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.20.22279903
4099  - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22279903.short
4100  - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22279903.full
AB  - BACKGROUND Over 20% of cases and 0.4% of deaths from Covid-19 occur in children. Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein vaccine NVX-CoV2373 in adults, the PREVENT-19 trial enrolled adolescents.METHODS Safety, immunogenicity, and efficacy of NVX-CoV2373 were evaluated in adolescents aged 12 to <18 years in an expansion of PREVENT-19, a phase 3, randomized, observer-blinded, placebo-controlled trial in the United States. Participants were randomized 2:1 to two doses of NVX-CoV2373 or placebo 21 days apart, and followed for a median of 2 months after second vaccination. Primary end points were serologic non-inferiority of neutralizing antibody (NA) responses compared with young adults (18 to <26 years) in PREVENT-19, protective efficacy against laboratory-confirmed Covid-19, and assessment of reactogenicity/safety.RESULTS Among 2,247 participants randomized between April–June 2021, 1,491 were allocated to NVX-CoV2373 and 756 to placebo. Post-vaccination, the ratio of NA geometric mean titers in adolescents compared to young adults was 1.5 (95% confidence interval [CI] 1.3 to 1.7). Twenty Covid-19 cases (all mild) occurred: 6 among NVX-CoV2373 and 14 among placebo recipients (vaccine efficacy [VE]: 79.5%, 95% CI, 46.8 to 92.1). All sequenced viral genomes (11/20) were identified as Delta variant (Delta variant VE: 82.0% [95% CI: 32.4 to 95.2]). Reactogenicity was largely mild-to-moderate, transient, and more frequent in NVX-CoV2373 recipients and after the second dose. Serious adverse events were rare and evenly distributed between treatments.CONCLUSIONS NVX-CoV2373 was safe, immunogenic, and efficacious in the prevention of Covid-19 and those cases caused by the Delta variant in adolescents.(Funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; PREVENT-19 ClinicalTrials.gov number, NCT04611802).Competing Interest StatementDisclosure forms provided by the authors will be available with the full text of this article upon publication.Clinical TrialNCT04611802Funding StatementSupported by Novavax, Inc., the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) (contract number: OWS: Novavax Project Agreement No.1 under its Medical CBRN Defense Consortium (MCDC) Base Agreement No. 2020-530; Department of Defense (DoD) No. W911QY20C0077); and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI68614), the HVTN Statistics and Data Management Center (UM1 AI68635), the HVTN Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI68636), and the Infectious Diseases Clinical Research Consortium leadership group (UM1 AI148684). Editorial assistance on the preparation of this manuscript was provided by Kelly Cameron, PhD, and Rebecca Harris, PhD, of Ashfield MedComms, an Inizio company, supported by Novavax, IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following Institutional Review Board / Independent Ethics committee reviewed and approved the study: Western Copernicus Group IRB, US. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA data-sharing statement provided by the authors will be available with the full text of this article upon publication (https://clinicaltrials.gov/ct2/show/NCT04611802). https://clinicaltrials.gov/ct2/show/NCT04611802